Tango Therapeutics, Inc. (TNGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 8, 2022, details the results of the 2022 Annual Meeting of Stockholders held virtually on June 8, 2022. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
As of the record date (April 11, 2022), 87,712,630 shares of Common Stock were outstanding. At the Annual Meeting, 81,740,796 shares (93.19%) were present or represented by proxy, establishing a quorum. Stockholders voted on two proposals:
- Proposal 1 (Election of Directors): Lesley Ann Calhoun and Reid Huber were elected as Class I directors.
- Lesley Ann Calhoun: 74,549,730 votes FOR; 2,532,608 votes WITHHELD; 4,658,458 Broker Non-Votes.
- Reid Huber: 74,547,606 votes FOR; 2,534,732 votes WITHHELD; 4,658,458 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): The selection of PricewaterhouseCoopers, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, was ratified.
- Results: 81,737,938 votes FOR; 400 votes AGAINST; 2,458 votes ABSTAIN.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of shareholder vote outcomes.
Key Facts for Investor Verification
- Confirmation that Lesley Ann Calhoun and Reid Huber have officially joined the Board of Directors as Class I directors.
- Verification of PricewaterhouseCoopers, LLP's engagement as the independent auditor for the 2022 fiscal year.
- Review of the full Proxy Statement (filed April 26, 2022) for detailed biographical information on the new directors and the rationale for the auditor selection.